

1           **Restoration of leukomonocyte counts is associated with viral**  
2                           **clearance in COVID-19 hospitalized patients**

3

4    Xiaoping Chen<sup>1</sup>, Jiaxin Ling<sup>2</sup>, Pingzheng Mo<sup>1</sup>, Yongxi Zhang<sup>1</sup>, Qunqun  
5    Jiang<sup>1</sup>, Zhiyong Ma<sup>1</sup>, Qian Cao<sup>1</sup>, Wenjia Hu<sup>1</sup>, Shi Zou<sup>1</sup>, Liangjun Chen<sup>3</sup>,  
6    Lei Yao<sup>4</sup>, Mingqi Luo<sup>1</sup>, Tielong Chen<sup>1</sup>, Liping Deng<sup>1</sup>, Ke Liang<sup>1</sup>, Shihui  
7    Song<sup>1</sup>, Rongrong Yang<sup>1</sup>, Ruiying Zheng<sup>1</sup>, Shicheng Gao<sup>1</sup>, Xien Gui<sup>1</sup>,  
8           Hengning Ke<sup>1</sup>, Wei Hou<sup>4</sup>, Åke Lundkvist<sup>2</sup>, Yong Xiong<sup>1</sup>

9

10   <sup>1</sup> Department of Infectious Diseases, Zhongnan Hospital of Wuhan  
11   University, No.169, Donghu Road, Wuchang District, 430071 Wuhan,  
12   Hubei Province, China

13   <sup>2</sup> Department of Medical Biochemistry and Microbiology, Zoonosis  
14   Science Center, University of Uppsala, Uppsala, Sweden

15   <sup>3</sup> Department of Laboratory Medicine, Zhongnan Hospital of Wuhan  
16   University, Wuhan, People's Republic of China

17   <sup>4</sup> State Key Laboratory of Virology/ Institute of Medical Virology/ Hubei  
18   Province Key Laboratory of Allergy and Immunology, School of Basic  
19   Medical Sciences, Wuhan University, 185 Donghu Road, Wuhan 430071,  
20   Hubei Province, China

21

22

23 Corresponding to:

24 Xiaoping Chen, MD & PhD

25 E-mail address; [alackcn@126.com](mailto:alackcn@126.com)

26 Tel: 86-27-67812880

27 Address: Department of infectious diseases, Zhongnan Hospital of

28 Wuhan University, No.169, Donghu Road, Wuchang District, Wuhan

29 City, Hubei Province, P.R China.

30

31 Yong Xiong, MD & PhD

32 E-mail address; [yongxiong64@163.com](mailto:yongxiong64@163.com)

33 Tel: 86-27-67812880

34 Address: Department of infectious diseases, Zhongnan Hospital of

35 Wuhan University, No.169, Donghu Road, Wuchang District, Wuhan

36 City, Hubei Province, P.R China.

37

38

## 39 **Summary**

40 *Background:* Viral clearance is one important indicator for the recovery  
41 of SARS-CoV-2 infected patients. Previous studies have pointed out that  
42 suboptimal T and B cell responses can delay viral clearance in MERS-  
43 CoV and SARS-CoV infected patients. The role of leukomonocytes in  
44 viral clearance of COVID-19 patients is not yet well defined.

45 *Methods:* From January 26 to February 28, 2020, an observational study  
46 was launched at the Department of Infectious Diseases, Zhongnan  
47 Hospital of Wuhan University, Wuhan, China. We enrolled 25  
48 laboratory-confirmed COVID-19 patients, whose throat-swab specimens  
49 were tested positive for SARS-CoV-2 infection by qRT-PCR. To  
50 investigate the factors that contribute to the viral clearance, we  
51 comprehensively analyzed clinical records, counts of lymphocyte subsets  
52 including CD3+, CD4+, CD8+ T cells, B cells and NK cells in the  
53 patients who successfully cleared SARS-CoV-2, and compared to those  
54 that failed to, after a standardized treatment of 8-14 days.

55 *Findings:* In 25 enrolled COVID-19 patients, lymphopenia was a  
56 common feature. After the treatment, 14 out of the 25 enrolled patients  
57 were tested negative for SARS-CoV-2. The patients that cleared the  
58 infection had restored the numbers of CD3+, CD4+, CD8+ T cells and B

59 cells as compared to the still viral RNA positive patients, while the  
60 recovered patients had a higher count of leukomonocytes.

61 *Conclusions:* By comparison of leukomonocytes counts in COVID-19  
62 patients at different stages of the disease, we found that CD3+, CD4+,  
63 CD8+ T cells and B cells appear to play important roles in viral clearance.  
64 The restoration of leukomonocytes counts from peripheral blood can be  
65 used as prognosis for the recovery of an COVID-19 infection. We  
66 propose that restoration of leukomonocytes counts can be added to the  
67 COVID-19 diagnostic guidance as a criterion for releasing and  
68 discharging patients.

69 **Keywords.** COVID-19; SARS-CoV-2, leukomonocytes; viral clearance.

## 70 **Funding**

71 This study was funded by the Zhongnan Hospital of Wuhan University  
72 Science, Technology and Innovation Seed Fund, grant number  
73 znp2018007 and the Swedish Research Council, grant number 2017-  
74 05807. The funders had no role in study design, data collection or  
75 analysis, decision to publish or preparation of the manuscript. The authors  
76 declared no competing interests.

## 77 **Introduction**

78 In December 2019, a cluster of novel coronavirus-associated pneumonia  
79 cases was emerging in Wuhan, China [1]. The disease rapidly spread  
80 from Wuhan and caused a wide epidemic in China. The World Health  
81 Organization (WHO) has recently named the disease as Coronavirus  
82 Disease-2019 (COVID-19) [2]. The etiology of the disease is a novel  $\beta$ -  
83 coronavirus, taxonomically named as severe acute respiratory syndrome  
84 coronavirus 2 (SARS-CoV-2). Until February 29, 2020, SARS-CoV-2  
85 causes an epidemic worldwide. More than 80,000 people in over 60  
86 countries or territories have been contracted of COVID-19, and more  
87 than 3000 people have died [3].

88 The clinical manifestations of COVID-19 cases range from an  
89 asymptomatic course to severe acute respiratory symptoms and even acute  
90 respiratory failure [4-7]. Transmission occurs from human to human with  
91 nosocomial transmissions. The incubation time of COVID-19 has been  
92 reported from 0 to 24 days and also asymptomatic carriers can be  
93 infectious [8].

94 As a zoonotic virus, the natural host of SARS-CoV-2 is believed to be  
95 bats [9], however, the process of cross-species transmission(s) is still not  
96 known. The very first cases were associated with the Huanan Seafood  
97 Wholesale Market in Wuhan, China [10]. There is no effective antiviral

98 drug available yet. Although the pathogenesis of COVID-19 is still  
99 unclear, lymphopenia has been found in most COVID-19 patients [10-12].  
100 This feature has also been found in the other two fatal human coronavirus  
101 infections caused by severe acute respiratory syndrome coronavirus  
102 (SARS-CoV) and the Middle East respiratory syndrome coronavirus  
103 (MERS-CoV) [13, 14]. Previous studies showed that T cells, especially  
104 CD4+ and CD8+ T cells, play a significant antiviral role in balancing the  
105 combat against MERS-CoV or SARS-CoV infections [15]. These results  
106 suggested that leukomonocytes counts could be critical indicators  
107 associated with severity and the disease outcome. In this study, we  
108 retrospectively analyzed 25 COVID-19 cases to elucidate the dynamic of  
109 lymphocyte subset changes in the peripheral blood and their roles during  
110 the viral clearance.

111

## 112 **Methods**

### 113 *Study design*

114 From January 26 to February 28, 2020, 25 COVID-19 patients who had  
115 been repeatedly analyzed for lymphocyte subsets and SARS-CoV-2 RNA  
116 were enrolled in the study. Informed consents were obtained from all

117 patients upon admission to the Department of Infectious Diseases,  
118 Zhongnan Hospital of Wuhan University, Wuhan, China.

119

#### 120 *Data collection*

121 The medical records, including epidemiological and demographic  
122 information, clinical manifestations, laboratory data, and outcome of  
123 disease, were collected. To avoid subjective biases, two investigators  
124 reviewed the data independently and made a final consensus.

125 Peripheral blood (100  $\mu$ l) was collected from patients at admission to  
126 hospital and after 7 – 10 days of standard therapy (Version 6, 2020 Feb  
127 18,

128 [http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351](http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml)  
129 [d7da8aefc2.shtml](http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml)). Lymphocyte subsets such as CD3+, CD4+, CD8+ T  
130 cells, B cells and NK cells were stained by using the BD Multitest™ IMK  
131 kit (BD Ltd., San Jose, CA, USA) according to the manufacturer's  
132 instruction. The lymphocyte subset analyses were performed by flow  
133 cytometry (BD FACSCanto™ II Flow Cytometer).

134 Serial throat-swab samples were taken from patients at the admission to  
135 hospital during 8 – 14 days of standardized treatment (see Table 1)  
136 according to the recommendation in the guideline. The swab samples

137 were placed in 150  $\mu$ L of virus preservation solution and viral RNA  
138 subsequently extracted as described earlier [5, 16]. Two target genes of  
139 the SARS-CoV-2 genome, including the open reading frame 1ab  
140 (ORF1ab) and the nucleocapsid protein (N) gene, were simultaneously  
141 amplified and tested in the real-time RT-PCR assay by using a SARS-  
142 CoV-2 nucleic acid detection kit according to the manufacturer's protocol  
143 (Shanghai Bio-Germ Medical Technology Co Ltd, Shanghai, China). The  
144 reaction mixture consisted of 12  $\mu$ L reaction buffer, 4  $\mu$ L of enzyme  
145 solution, 3  $\mu$ L of diethyl pyrocarbonate-treated water, 2  $\mu$ L of RNA  
146 template, and 4  $\mu$ L of probe/primers solution, which contained two sets of  
147 probe primers: one set targets towards to ORF1ab (forward prime 5'-  
148 CCCTGTGGGTTTTACTTAA-3'; reverse primer 5'-  
149 ACGATTGTGCATCAGCTGA-3'; and the probe 5'-VIC-  
150 CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3'), and another  
151 targets towards to N (forward primer 5'-  
152 GGGGAAGTTCTCCTGCTAGAAT-3'; reverse primer 5'-  
153 CAGACATTTTGCTCTCAAGCTG-3'; and the probe 5'-FAM-  
154 TTGCTGCTGCTTGACAGATT-TAMRA-3').

155 The results of the real-time RT-PCR analyzes were interpreted as: a  
156 cycle threshold value (Ct-value) less than 37 was defined as a positive  
157 result; a Ct-value of 40 or more was defined as a negative result; a



158 medium load result, defined as a Ct-value of 37 to less than 40, required  
159 another test for confirmation. The patients who repeatedly tested SARS-  
160 CoV-2 RNA negative for at least two times with an interval of more than  
161 1 day were regarded as viral negative. These diagnostic criteria were  
162 based on the recommendation by the National Institute for Viral Disease  
163 Control and Prevention, China  
164 (<http://ivdc.chinacdc.cn/gjhz/jldt/202002/P020200209712430623296.pdf>).

#### 165 *Statistical analysis*

166 We used the SPSS 17.0 software package for the statistical analyses. We  
167 used  $X^2$  tests or Fisher's exact tests for categorical variables. For  
168 measurement of the data, a normal distribution was tested first and then  
169 proceeded to t-test, expressed as the mean  $\pm$  standard deviations;  
170 otherwise the Mann-Whitney U test was used for non-normal distribution  
171 data, expressed in terms of median (25%–75% interquartile range, IQR).  
172 A p value of  $< 0.05$  was considered statistically significant.

173

#### 174 *The principle of medical ethics*

175 This study was approved by the ethics board in Zhongnan Hospital of  
176 Wuhan University, Wuhan, China (No.2020011).

177

## 178 **Results**

### 179 *Baseline Characteristics of COVID-19 patients*

180 A total of 25 patients, 11 men and 14 women were enrolled in this study  
181 (Table 1). The ages of the patients spanned from 25 to 80 years (average  
182  $51.4 \pm 16.6$  years). Fourteen people described a previous exposure history  
183 to the source of infection, either from the Huanan Seafood Wholesale  
184 Market or through direct contacts with COVID-19 patients. The most  
185 common symptoms at the onset of illness were: fatigue (80.0%), fever  
186 ( $37.4\text{--}39.1^\circ\text{C}$ , 75.0%), myalgia (68.0%), cough (64.0%), and less  
187 common: dyspnea (28.0%) and diarrhea (20.0%). Seven cases had  
188 underlying diseases such as hypertension, cardiovascular disease,  
189 diabetes, malignancy or chronic liver disease (Table 1).

### 190 **Laboratory analysis before and after treatment**

191 Laboratory analysis were performed before the treatment. The  
192 biochemical tests included alanine aminotransferase, aspartate  
193 aminotransferase, aspartate aminotransferase, creatinine, and D-dimer,  
194 which all were found normal (Table 2). However, blood counts of the  
195 patients showed leucopenia ( $4.5 \pm 1.9 \times 10^9/\text{L}$ ) and lymphopenia ( $< 1.3$   
196  $\times 10^9/\text{L}$ ). The counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, B  
197 cells, and NK cells were found lower than normal values. Interleukin-6

198 had increased to a mean of 16.1 (3.7 – 31.4) pg/ml. Five patients had an  
199 increase of procalcitonin ( $\geq 0.05$  ng/mL) (Table 2).

200 The treatment was mainly of supportive care (Table 1). Twenty-four  
201 patients were given antiviral therapy including arbidol (orally, 200 mg,  
202 three times per day), and oxygen support. Antibiotic therapy, both orally  
203 and intravenous, were given as described in Table 1. Fourteen patients  
204 received corticosteroids to suppress an excessive inflammatory activation.  
205 After standardized treatment of 8–14 days, according to the laboratory  
206 analysis of viral RNA, fourteen patients showed viral clearance and 11  
207 patients were still positive for SARS-CoV-2 viral RNA (Table 1).

208 When comparing the group that showed viral clearance and the group that  
209 failed, we found no significant association to sex, epidemiological  
210 exposure history, comorbidities, onsets of signs and symptoms, or  
211 treatment, but with the age and days of hospitalization. The mean days of  
212 hospitalization in the group that showed viral clearance were 12 days  
213 (10.0 – 15.0), which was shorter as compared to the group that failed to  
214 clear the virus, for which the average days were 21 (18.0 – 23.0) days.  
215 Age can play an important role during the viral clearance: patients  
216 without viral clearance were older ( $60.2 \pm 16.9$ , y) than patients with viral

217 clearance ( $44.5 \pm 13.0$  y), showing a statistically significant difference  
218 (Table 1).

219 **Association between peripheral lymphocyte counts and disease**  
220 **outcomes**

221 Since lymphopenia was found in all the patients in the current study and  
222 also earlier reported elsewhere [10], we further analyzed the association  
223 between peripheral lymphocyte counts and disease outcomes. In the 14  
224 patients with viral clearance after the 8 – 14 days of treatment, the counts  
225 of CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells were restored  
226 close to normal levels and with a significant difference as compared to  
227 the counts at admission in 12 patients. In the remaining 2 patients with  
228 viral clearance the leukomonocytes counts were still at low levels (Figure  
229 1, A-E). However, in the patients without viral clearance (No.=11), no  
230 differences were seen before and after treatment regarding the CD3+,  
231 CD4+, CD8+, B, and NK cell counts (Figure 1, F-J). The association  
232 between peripheral lymphocyte counts and viral detection suggested that  
233 higher counts of CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells  
234 had a significant impact on the viral clearance.

235

236 To further monitor the disease outcome of those 11 patients who were  
237 still positive for SARS-CoV-2 virus RNA, we extended the same  
238 treatment to 15 – 23 days (Figure 2). At 15 –23 days, 7 patients were  
239 negative for viral RNA detection (data for leukomonocyte subsets was  
240 available for 6 of these 7 patients), but 4 patients were still positive (all  
241 these four had been tested for leukomonocyte subsets). The 4 viral RNA  
242 positive patients had low counts of CD3+ T cells ( $< 1200 \times 10^9/L$ ), CD4+  
243 T cells ( $< 700 \times 10^9/L$ ), CD8+ T cells ( $< 500 \times 10^9/L$ ), B cells ( $< 400$   
244  $\times 10^9/L$ ), and NK cells ( $< 400 \times 10^9/L$ ). Due to the small sample size, no  
245 statistically significant differences for the cell counts were observed,  
246 except for the NK cell counts, which showed a significant decrease in the  
247 4 viral RNA positive patients (Figure 2, J). However, we found a similar  
248 trend that the increased counts of CD3+ T cells and CD8+ T cells  
249 corresponded to cases which were negative for viral RNA detection (5  
250 out of 6). One case that still had low counts of CD3+ T cells, CD4+ T  
251 cells, CD8+ T cells, B cells and NK cells was found negative for viral  
252 RNA.

253

## 254 **Clinical outcome**

255 We observed the clinical course of 25 COVID-19 patients within 23 days  
256 of treatment. During the first phase of treatment, at 8 – 14 days, fourteen

257 patients showed viral clearance and 12 of them were discharged from the  
258 hospital according to the guideline. The treatment of oxygen support  
259 therapy and clinical observation was continued for the remaining 2  
260 patients in this group. Eleven viral RNA positive patients received a  
261 second phase of treatment between 15– 23 days. Until February 28, 7 of  
262 these 11 patients turned out to be viral RNA negative. Four of these 7  
263 patients were then discharged from the hospital, while the other 3 (one  
264 had a liver disease and the other two still had significant clinical  
265 symptoms), together with the 4 patients who were still positive for viral  
266 RNA, were kept under treatment (Table 1). In total, 9 out of the 25  
267 COVID-19 patients were still hospitalized after 23 days of clinical  
268 treatment.

269

## 270 **DISCUSSION**

271 In this report, we retrospectively investigated the changes of CD3+,  
272 CD4+, CD8+, B, and NK cell counts in peripheral blood of 25 COVID-  
273 19 patients during the viral infection and the mechanisms for viral  
274 clearance. We found that restoration of CD3+, CD4+, CD8+ T cells, B  
275 cells and NK cells was associated the viral clearance in COVID-19  
276 patients.

277 According to the Guideline of the treatment of COVID-19 (Version 6,  
278 2020 Feb 18,  
279 [http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351](http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml)  
280 [d7da8aefc2.shtml](http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2.shtml)), the diagnosis of COVID-19 infection is based on an  
281 epidemiological history of contact with COVID-19 patients or travel to  
282 endemic areas, combined with laboratory testing including viral RNA  
283 detection and radiological findings. COVID-19 patients have similarities  
284 of the clinical features with other coronavirus infections. Most patients  
285 had fever, cough, myalgia and fatigue, and less often showed symptoms  
286 of dyspnoea, haemoptysis and diarrhea [10]. Half of the cases had  
287 comorbidities such as diabetic, hypertension and cardiovascular diseases  
288 [10]. In our study, we also found some cases that had underlying diseases  
289 but without any association with the disease outcome. Age is a risk factor  
290 for a more severe disease outcome, because of the generally inferior  
291 function of the immune system among older people. Based on the  
292 guideline, the patients who have normal body temperature for more than  
293 three days, mitigation of respiratory symptoms, improvement of  
294 radiological evidences for lesions, and had been tested negative for  
295 specific SARS-CoV-2 RT-PCR at least twice, can be discharged from the  
296 hospital. The average hospitalized time was 17 days (IQR 11.5 – 21.5),  
297 and even as long as 23 days for the patients that were released from our  
298 study [5], suggesting the time for SARS-CoV-2 clearance is also around

299 17 days or longer. This was also been observed in an earlier study where  
300 the shedding of SARS-CoV-2 in saliva continued up to 11 days [17].

301 Until now, there is no effective antivirals available against SARS-CoV-2.  
302 To eliminate the virus an effective immunological response with a  
303 minimum of immunopathological effects is required [18]. The antigen  
304 presentation requires inhibitory alveolar macrophages and dendritic cells  
305 (DCs). Successful stimulation can produce viral specific CD4 T cells,  
306 which are involved in the development of a specific humoral response,  
307 including neutralizing antibodies that can block the viral entry to the cells  
308 [19]. CD8+ cytotoxic T cells are required for recognition and killing of  
309 the infected cells, further playing a crucial role in SARS-CoV clearance  
310 [20, 21]. However, in the biopsy samples from the patients who died of  
311 COVID-19, histological examination showed pulmonary oedema with  
312 hyaline membrane formation, and interstitial mononuclear inflammatory  
313 infiltrates in the lung tissue, suggesting that acute respiratory failure was  
314 the cause of death, underlying mechanism that an over-activated  
315 immunity injured the lung tissue [12]. Among SARS patients, high  
316 expression of dysregulated chemokines and cytokines were found in  
317 blood and lungs [22], due to the reason of aberrant immune response  
318 caused by the viruses [13, 14]. The delayed or suboptimal immune  
319 responses would make chances for SARS-CoV and MERS-CoV to



320 escape from the immune responses, and survive and replicate in the host  
321 cells, leading a further delay of the viral clearance [15, 23]. In our study,  
322 COVID-19 patients at older ages needed a longer time for the recovery,  
323 likely due to the fact that aging is associated with a set of functional and  
324 structural alterations in the immune system [24]. Immune-modulators, as  
325 corticosteroids, have been empirically used in both SARS and COVID-19  
326 patients [10, 25]. Since corticosteroids might have a decline effect of  
327 circulating specific B and T cell subsets [26], the usage on COVID-19  
328 patients should be carefully evaluated before considered [12, 27].

329 A rapid and generalized lymphopenia has been observed as a prominent  
330 part in SARS-CoV and MERS infections [28]. Lymphopenia has also  
331 been observed in other viral infections such as measles virus and avian  
332 influenza virus, swine foot-and-mouth disease virus, respiratory syncytial  
333 virus, and HIV [29-33]. The possible reasons would be lymphocyte  
334 sequestration in the lung tissues, or immune-mediate lymphocyte  
335 destruction. In MERS infections, the function of bone marrow or thymus  
336 suppressed, and furthermore, T cells underwent apoptosis [34-36]. In  
337 COVID-19 patients, peripheral CD4 and CD8 T cell counts were found  
338 decreased but, they were also hyperactivated, which could result in severe  
339 immune injuries [12].

340 In the present study, we followed the current guidelines and used a  
341 specific SARS-CoV-2 realtime RT-PCR for viral detection. Surprisingly,  
342 one lymphopenia patient (37y, male, chronic liver disease) was found  
343 negative by the realtime RT-PCR and his symptoms had been improved  
344 but he is still in hospital. Until now, specific viral RNA detection based  
345 on realtime RT-PCR is commonly used in the clinical diagnosis. The  
346 usage of realtime RT-PCR is versatile in the detection of SARS-CoV-2 in  
347 the respiratory tract specimen or throat swab, but we must keep in mind  
348 that those methods always are followed by the probability of false  
349 positive/negative. Besides, around 14% of the discharged COVID-19  
350 patients were tested as positive again on follow up samples  
351 ([https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-](https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-patients-in-guangdong-tested-positive-again-101520415.html)  
352 [patients-in-guangdong-tested-positive-again-101520415.html](https://www.caixinglobal.com/2020-02-26/14-of-recovered-covid-19-patients-in-guangdong-tested-positive-again-101520415.html)), showing  
353 the recurrence of SARS-CoV-2. This imply that viral detection cannot be  
354 used as a single criterion for COVID-19 diagnosis. As a highly  
355 contiguous disease with a fatality of approximately 2.3% and up to 49.0%  
356 in critical cases [7], every hospitalized COVID-19 patient must be  
357 evaluated carefully before discharged. The peripheral leukomonocytes  
358 counts could provide more information in the evaluation of COVID-19  
359 patients.

360 In conclusion, we retrospectively analyzed 25 COVID-19 cases and  
361 found that restoration of peripheral leukomonocytes could help the  
362 clearance of SARS-CoV-2. We propose here that leukomonocytes counts  
363 may serve as a valid prognosis of immune reconstitution for recovery of  
364 COVID-19 infection and that can update the current COVID-19 diagnosis  
365 guideline.

366

## 367 Acknowledgement

368 An especially strong appreciation goes to all the clinical physicians,  
369 health caregivers, clinical laboratory personals, epidemiologists, and  
370 researchers who have been fighting against the SARS-CoV-2 epidemic.  
371 We also acknowledge the supports from both nationwide and  
372 international resources.

373

## 374 Reference

- 375 1. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of  
376 Novel Coronavirus-Infected Pneumonia. *N Engl J Med* **2020**.
- 377 2. Naming the coronavirus disease (COVID-2019) and the virus that causes it.  
378 Available at: [https://www.who.int/emergencies/diseases/novel-coronavirus-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
379 [2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
380 [the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it).
- 381 3. Available at: <https://promedmail.org/>.
- 382 4. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in  
383 patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63  
384 patients in Wuhan, China. *Eur Radiol* **2020**.
- 385 5. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized  
386 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.  
387 *JAMA* **2020**.
- 388 6. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with  
389 Pneumonia in China, 2019. *N Engl J Med* **2020**; 382(8): 727-33.
- 390 7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the  
391 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a  
392 Report of 72314 Cases From the Chinese Center for Disease Control and  
393 Prevention. *JAMA* **2020**.
- 394 8. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of  
395 COVID-19. *JAMA* **2020**.
- 396 9. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a  
397 new coronavirus of probable bat origin. *Nature* **2020**.
- 398 10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019  
399 novel coronavirus in Wuhan, China. *Lancet* **2020**; 395(10223): 497-506.
- 400 11. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated  
401 with the 2019 novel coronavirus indicating person-to-person transmission: a  
402 study of a family cluster. *Lancet* **2020**; 395(10223): 514-23.
- 403 12. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with  
404 acute respiratory distress syndrome. *Lancet Respir Med* **2020**.

- 405 13. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with  
406 severe acute respiratory syndrome: retrospective analysis. *BMJ* **2003**;  
407 326(7403): 1358-62.
- 408 14. Lau SK, Lau CC, Chan KH, et al. Delayed induction of proinflammatory  
409 cytokines and suppression of innate antiviral response by the novel Middle  
410 East respiratory syndrome coronavirus: implications for pathogenesis and  
411 treatment. *J Gen Virol* **2013**; 94(Pt 12): 2679-90.
- 412 15. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the  
413 pathology and pathogenesis of the emerging human pathogenic  
414 coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *J Med Virol* **2020**.
- 415 16. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical  
416 transmission potential of COVID-19 infection in nine pregnant women: a  
417 retrospective review of medical records. *The Lancet* **2020**.
- 418 17. To KK, Tsang OT, Chik-Yan Yip C, et al. Consistent detection of 2019 novel  
419 coronavirus in saliva. *Clin Infect Dis* **2020**.
- 420 18. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory  
421 virus infection: balancing virus clearance and immunopathology. *Semin*  
422 *Immunopathol* **2016**; 38(4): 471-82.
- 423 19. Chen J, Lau YF, Lamirande EW, et al. Cellular immune responses to severe  
424 acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent  
425 BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. *J*  
426 *Virol* **2010**; 84(3): 1289-301.
- 427 20. Janice Oh HL, Ken-En Gan S, Bertoletti A, Tan YJ. Understanding the T cell  
428 immune response in SARS coronavirus infection. *Emerg Microbes Infect* **2012**;  
429 1(9): e23.
- 430 21. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from  
431 clinical disease and for virus clearance in severe acute respiratory syndrome  
432 coronavirus-infected mice. *J Virol* **2010**; 84(18): 9318-25.
- 433 22. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles  
434 of severe acute respiratory syndrome. *Am J Respir Crit Care Med* **2005**;  
435 171(8): 850-7.
- 436 23. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral  
437 shedding and immunological responses in MERS patients representing a  
438 broad spectrum of disease severity. *Sci Rep* **2016**; 6: 25359.
- 439 24. Sadighi Akha AA. Aging and the immune system: An overview. *J Immunol*  
440 *Methods* **2018**; 463: 21-6.
- 441 25. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment  
442 effects. *PLoS Med* **2006**; 3(9): e343.
- 443 26. Olnes MJ, Kotliarov Y, Biancotto A, et al. Effects of Systemically Administered  
444 Hydrocortisone on the Human Immune. *Sci Rep* **2016**; 6: 23002.
- 445 27. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human  
446 respiratory disease in China. *Nature* **2020**.
- 447 28. Li T, Qiu Z, Zhang L, et al. Significant changes of peripheral T lymphocyte  
448 subsets in patients with severe acute respiratory syndrome. *J Infect Dis* **2004**;  
449 189(4): 648-51.
- 450 29. Okada H, Kobune F, Sato TA, et al. Extensive lymphopenia due to apoptosis  
451 of uninfected lymphocytes in acute measles patients. *Arch Virol* **2000**; 145(5):  
452 905-20.
- 453 30. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of  
454 avian influenza A (H5N1) viruses in ferrets. *J Virol* **2002**; 76(9): 4420-9.

- 455 31. Bautista EM, Ferman GS, Golde WT. Induction of lymphopenia and inhibition  
456 of T cell function during acute infection of swine with foot and mouth disease  
457 virus (FMDV). *Vet Immunol Immunopathol* **2003**; 92(1-2): 61-73.
- 458 32. O'Donnell DR, Carrington D. Peripheral blood lymphopenia and neutrophilia in  
459 children with severe respiratory syncytial virus disease. *Pediatr Pulmonol*  
460 **2002**; 34(2): 128-30.
- 461 33. Li CX, Li YY, He LP, et al. The predictive role of CD4(+) cell count and  
462 CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients  
463 receiving antiretroviral therapy: an eight-year observation in China. *BMC*  
464 *Immunol* **2019**; 20(1): 31.
- 465 34. He Z, Zhao C, Dong Q, et al. Effects of severe acute respiratory syndrome  
466 (SARS) coronavirus infection on peripheral blood lymphocytes and their  
467 subsets. *Int J Infect Dis* **2005**; 9(6): 323-30.
- 468 35. Yang Y, Xiong Z, Zhang S, et al. Bcl-xL inhibits T-cell apoptosis induced by  
469 expression of SARS coronavirus E protein in the absence of growth factors.  
470 *Biochem J* **2005**; 392(Pt 1): 135-43.
- 471 36. Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome  
472 Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine  
473 Development. *J Immunol Res* **2019**; 2019: 6491738.

474

475

476 **Table 1.** Demographics, baseline characteristics, treatment, and clinical  
 477 outcomes of 25 patients infected with SARS-CoV-2

	Total (n=25)	Viral clearance (n=14) <sup>a</sup>	without viral clearance (n=11) <sup>a</sup>	P value
<b>Sex</b>				
female	14(56.0%)	9(64.3%)	5(45.5%)	0.435
male	11(44.0%)	5(35.7%)	6(54.5%)	
<b>Huanan Seafood Wholesale</b>	14 (56.0%)	9 (64.3%)	5 (45.5%)	0.697
<b>Market or patient infected with SARS-CoV-2 exposure</b>				
<b>Age, mean ±SD, y</b>	51.4±11.6	44.5±13.0	60.2±16.9	<b>0.015</b>
<b>Comorbidities</b>				
Hypertension	3(12.0%)	0(0.0%)	3(25.0%)	0.072
Cardiovascular disease	2(8.0%)	1(7.0%)	1(9.1%)	1.000
Diabetes	2(8.0%)	0(0.0%)	2(18.2%)	0.183
Malignancy	1(4.0%)	0(0.0%)	1(9.1%)	0.440
COPD	0(0.0%)	0(0.0%)	0(0.0%)	-
Chronic liver disease	3(12.0%)	0(0.0%)	3(25.0%)	0.072
<b>Signs and symptoms</b>				
Fever	18 (75.0%)	8 (57.1%)	10 (90.9%)	0.090
Fatigue	20 (80.0%)	11 (78.6%)	9 (81.8%)	1.000
Myalgia	17 (68.0%)	8 (57.1%)	9 (81.8%)	0.234
Cough	16 (64.0%)	9 (64.3%)	5 (45.5%)	0.697
Dyspnea	7 (28.0%)	4 (28.6%)	3 (27.3%)	1.000
Diarrhea	5 (20.0%)	2 (14.3%)	3 (27.3%)	0.623

Headache	2 (8.0%)	0 (0.0%)	2 (13.3%)	0.183
Heart rate, mean $\pm$ SD, bpm	88.2 $\pm$ 15.1	86.8 $\pm$ 11.8	89.9 $\pm$ 18.9	0.617
Respiratory rate, median (IQR)	20.0 (19.0, 22.0)	20.0 (19.0, 22.0)	20.0 (19.0, 22.0)	0.845
Mean systolic blood pressure, mean $\pm$ SD, mm Hg	130.0 $\pm$ 24.4	126.8 $\pm$ 22.6	134.2 $\pm$ 27.1	0.464
<b>Days from illness onset to hospital, median (IQR), d</b>	6 (3,11)	8 (3,11)	6 (3,11)	1.000
<b>Hospital stays, median (IQR), d</b>	17.0 (11.5, 21.5)	12.0 (10.0,15.0)	21.0 (18.0,23.0)	<b>0.001</b>
<b>Treatment</b>				
Oxygen support	15 (60%)	6 (42.9%)	9 (81.8%)	0.099
Antiviral therapy	24(96.0%)	13(92.9%)	11(100.0%)	1.000
Antibiotic therapy	25(100.0%)	14(100.0%)	11(100.0%)	-
Use of corticosteroid	14 (56.0%)	6(42.9%)	8(72.7%)	0.227
<b>Clinical outcome<sup>b</sup></b>				
Remained in hospital	9(36.0%)	2(14.3%)	7(63.6%)	<b>0.017</b>
Discharged	16(64.0%)	12(85.7%)	4(36.4%)	

478

479 <sup>a</sup> After 7-14 days, viral clearance or not was determined by viral RNA detections.

480 <sup>b</sup> After 18-25 days, patients were discharged according to the guideline: 1) a series negative result of

481 viral RNA detection; 2) no clinical symptoms; 3) improved chest CT imaging.

482

483

484

485

486



487 **Table 2.** Laboratory results of 25 patients with the outcome of viral  
488 clearance.

	Normal Range	Total	Viral clearance(n=14)	without viral clearance (n=11)	P value
White blood cell Count ( $\times 10^9$ /L)	3.5-9.5	4.5 $\pm$ 1.9	4.5 $\pm$ 1.7	4.5 $\pm$ 2.2	0.919
Lymphocyte count ( $\times 10^9$ /L)	1.1-3.2	<b>0.9 (0.6, 1.3)</b>	0.8 (0.6, 1.4)	0.9 (0.6, 1.2)	0.565
Monocyte count ( $\times 10^9$ /L)	0.1-0.6	0.37 $\pm$ 0.15	0.33 $\pm$ 0.15	0.42 $\pm$ 0.14	0.117
Neutrophil count ( $\times 10^9$ /L)	1.8-6.3	2.8 (1.5, 4.5)	3.1 (1.6, 4.8)	2.6 (1.3, 4.3)	0.805
Platelet count ( $\times 10^9$ /L)	125-350	179.5 $\pm$ 68.8	191.5 $\pm$ 70.4	164.3 $\pm$ 66.7	0.336
Alanine aminotransferase (U/L)	9-50	24 (20.5, 38.5)	21 (19, 50.5)	25 (21.0, 35.0)	0.583
Aspartate aminotransferase (U/L)	15-40	26 (21.0, 33.0)	23.0(17.0, 34.8)	28.0(26.0,33.0)	0.066
Total bilirubin ( mmol/L)	5-21	9.6 (8.0, 12.7)	9.6 (7.6, 12.2)	10.7 (8.2, 16.7)	0.511
Lactate dehydrogenase (U/L)	125-243	197(164.5, 286.5)	197.0(155.0, 340.0)	201.0(174.0, 279.0)	0.956
Prothrombin time (s)	9.4-12.5	12.3 (11.7, 13.0)	12.6 (11.7,13.5)	12.3 (12.1,12.4)	0.641
Activated partial thromboplastin time (s)	25.1-36.5	29.9 $\pm$ 3.0	29.8 $\pm$ 2.6	30.0 $\pm$ 3.6	0.860
D-dimer, (mg/L)	0-500	187.0 (125.0,309.5)	181.0 (104.5,271.0)	233.0 (145.0,630.0)	0.179
Creatinine ( $\mu$ mol/L)	64-104	65.5 $\pm$ 14.6	64.3 $\pm$ 14.3	67.0 $\pm$ 15.6	0.659
Procalcitonin, ng/mL $\geq$ 0.05, No. (%)	<0.05	<b>5 (20.0%)</b>	3 (21.4%)	2 (18.2%)	1.000
Interleukin-6 (pg/ml)	0-7	<b>16.1 (3.7, 31.4)</b>	13.8 (5.3, 30.2)	17.6 (2.8, 49.9)	0.805
CD3+ T cell count ( $\times 10^9$ /L)	805-4459	<b>561.0 (338.0, 770.0)</b>	639.0 (400.3, 1038.0)	485.0 (384.0, 732.0)	0.311
CD4+ T cell count ( $\times 10^9$ /L)	345-2350	<b>297.0 (171.5, 447.5)</b>	327.0 (182.8, 560.5)	220.0 (148.0, 420.0)	0.262
CD8+ T cell count ( $\times 10^9$ /L)	345-2350	<b>272.9<math>\pm</math>129.7</b>	291.4 $\pm$ 149.3	249.5 $\pm$ 101.6	0.435
B cell count ( $\times 10^9$ /L)	240-1317	<b>111.5<math>\pm</math>75.8</b>	133.2 $\pm$ 84.8	83.8 $\pm$ 54.2	0.107
NK cell count ( $\times 10^9$ /L)	210-1514	<b>170.0 (67.5, 245.0)</b>	193.5 (75.0, 286.0)	170.0 (43.0, 215.0)	0.511

489

490

491

492 **Figure legends**

493 **Figure 1.** Comparison of peripheral changes in CD3+, CD4+, CD8+ T,  
494 B, and NK cell counts in patients who were negative for the SARS-CoV-  
495 2 (A-E) and positive (F-J) after 8-14 days of treatment. The medium  
496 number of peripheral lymphocyte counts are represented in the solid line.  
497 The threshold of normal peripheral lymphocyte counts is represented in  
498 the dash line. NS means no significant difference tested in statistical  
499 analysis: Mann-Whitney U test was used for A, B, E, F since these data  
500 are non-normal distributed and t-test was used for the other normal  
501 distributed data).

502

503 **Figure 2.** Comparison of peripheral changes in CD3+, CD4+, CD8+ T,  
504 B, and NK cell counts in six patients who were negative for the SARS-  
505 CoV-2 (A-E) and four patients who were positive (F-J) after 15-23 days  
506 of treatment. The medium number of peripheral lymphocyte counts are  
507 represented in the solid line. The threshold of normal peripheral  
508 lymphocyte counts is represented in the dash line. NS means no  
509 significant difference tested in statistical analysis and all data used Mann-  
510 Whitney U test.



